News & Press
A New Partnership to Fight Ewing SarcomaJan 1, 2013
C17 Research Council represents 16 academic pediatric oncology/haematology programs in their 17 centres across Canada. It is a network set up to encourage and develop collaborative, multi-disciplinary, multi-site, Canadian research in pediatric haematology, oncology and haematological stem cell transplantation in furthering C17's missions to improve health outcomes and quality of life for children and adolescents in Canada with cancer and blood disorders.
In August 2011, The Ewings Cancer Foundation of Canada (ECFC) formed its new partnership with C17 Council and the C17 Research Network to fund a research grant with the goal of improving the survival rate and quality of life of children and adolescence impacted by Ewing sarcoma cancer in Canada. The area of research may include clinical trials, disease registries, biological sample banks, quality of life, health outcomes, psychosocial research, or basic and translational research with a direct application into causes, treatment, cure or quality of life for the young lives with Ewing sarcoma.
Under this partnership, ECFC and the C17 Council have each provided $25,000 per year in funding for a dedicated C17 Research Network grant competition. Funding was awarded in January 2012 for a total grant of $100,000 over 2 years which is dedicated specifically for Ewing cancer research. JANUARY 2013 EWING GRANT UPDATE
Since August of 2012, Dr. Jason Berman and Poul Soresen have made excellent progress on the Ewings Cancer Foundation funded project in zebrafish and mouse models. They are submitting their first manuscript showing the role of the Y Box-1 binding protein (YB-1) in Ewing sarcoma metastasis. They have seen that these cancer cells spread to the tail and the lungs in both fish and mouse models when YB-1 is expressed, and that there is an absence of this spread when YB-1 is suppressed. They are optimizing the doses of standard chemotherapy agents used in Ewing sarcoma and will test whether YB-1 expression affects the response to these drugs.
They are studying the drug bevacizumab (Avastin) which reduces the growth of new blood vessels needed by tumours in zebrafish xenografts, to look at the effect of blocking blood vessel growth on tumour formation. In addition, they are studying a new compound that blocks the focal adhesion kinase protein (FAK), which can stop Ewing sarcoma cell proliferation. Their studies promise to provide new insights into the mechanisms underlying the aggressive behaviour of Ewing sarcoma and potential novel targets to interfere with the process.
This is truly history in the making.